Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
15 January 1998 | Volume 128 Issue 2 | Pages 156-157
Interferon-
Twenty-four patients (12 were positive for hepatitis B e antigen [HBeAg] and 12 were infected by the "e" minus mutant) with elevated serum alanine aminotransferase (ALT) levels and serum hepatitis B virus DNA (Abbott Laboratories, North Chicago, Illinois) were randomly assigned to receive vitamin E, 300 mg twice daily for 3 months (n = 12), or no treatment (n = 12). They were followed monthly for 9 months. Nineteen patients (10 in the vitamin E group and 9 controls) had been unsuccessfully treated with interferon-LETTER
Vitamin E for Chronic Hepatitis B
TO THE EDITOR:
for chronic hepatitis B is often ineffective and is associated with drawbacks, such as prolonged parenteral schedules, high costs, and side effects [1]. Oral vitamin E is an inexpensive antioxidant that can stimulate the immune response and does not induce side effects [2]. We evaluated vitamin E supplementation as therapy for chronic hepatitis B.
. At study entry, the study groups were similar with respect to demographic, clinical, and laboratory features. Four HBeAb-positive patients discontinued vitamin E therapy because of severe increases in ALT levels (>10-fold the normal upper limit). A similar finding was seen in 2 controls. The biochemical and virologic responses after 3 and 9 months are shown in the (Table 1). Of the 5 patients with complete response, 2 were positive for HBeAb and 3 were positive for HBeAg at study entry. The HBeAg-positive patients seroconverted to HBeAb during the study period, whereas none of the controls seroconverted from HBeAg to HBeAb. Three of 5 patients with complete response had not responded to previous interferon-
treatment. Treatment with vitamin E had no side effects. These results suggest that vitamin E is a safe and useful treatment for chronic hepatitis B. Although the mechanism through which these results were achieved is unknown, the stimulatory effect of vitamin E on the immune system probably played a major role. Further studies are needed to confirm these data and to evaluate the effects of a possible combination with other antiviral drugs.
|
Author and Article Information
|
|---|
|
|
|---|
References
|
|---|
|
|
|---|
1. Lok AS. Treatment of chronic hepatitis. Br J Virol Hepatol. 1994; 1:105-24.
2. Meydani M. Vitamin E. Lancet. 1995; 345:170-5.
About Letters
|
|
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
Include no more than 300 words of text, three authors, and five references
Type with double-spacing
Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
This article has been cited by other articles:
![]() |
S. Sered and P. Nikolaidis CT Findings of Perirenal Plasmacytoma Am. J. Roentgenol., September 1, 2003; 181(3): 888 - 888. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||